Table 3

Incidence of treatment-emergent adverse eventsa

Incidence, n (%)

Placebo (n = 50)

Milnacipran (n = 100)


Patients with ≥1 TEAE

29 (58)

47 (47)

Nausea

1 (2)

4 (4)

Headache

0

4 (4)

Vomiting

1 (2)

4 (4)

Sinusitis

3 (6)

4 (4)

Upper respiratory tract infection

2 (4)

4 (4)

Fatigue

1 (2)

4 (4)

Pain in extremity

1 (2)

4 (4)

Fall

0

4 (4)

Arthralgia

1 (2)

3 (3)

Fibromyalgia

1 (2)

3 (3)

Peripheral edema

3 (6)

2 (2)

Hypothyroidism

2 (4)

1 (1)

Influenza

2 (4)

1 (1)

Irritability

3 (6)

0

Neck pain

2 (4)

0


aReported in ≥3% of patients in either treatment group during the double-blind period. TEAE = treatment emergent adverse event.

Clauw et al. Arthritis Research & Therapy 2013 15:R88   doi:10.1186/ar4268

Open Data